Sirolimus-eluting coronary stent - Micell Technologies

Drug Profile

Sirolimus-eluting coronary stent - Micell Technologies

Alternative Names: MiStent; MiStent SES

Latest Information Update: 14 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Micell Technologies
  • Developer Micell Technologies; Stentys
  • Class Anti-infectives; Antiepileptic drugs; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • Phase III Coronary disorders

Most Recent Events

  • 01 Aug 2016 Micell Technologies completes the DESSOLVE II phase II trial for Coronary artery restenosis prevention in Belgium, France, the Netherlands, Sweden, United Kingdom and New Zealand (NCT01294748)
  • 22 Mar 2016 Micell completes enrolment in MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT) study trial for Coronary artery restenosis in USA
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top